Enovis reported a challenging fourth quarter with a significant net loss due to a $501 million non-cash goodwill impairment charge, despite achieving 3% reported sales growth. The company saw continued momentum in its Reconstructive segment while the Prevention & Recovery segment remained stable, and management highlighted positive free cash flow and debt reduction for the full year.

Enovis reported strong second-quarter 2025 results with net sales of $565 million, a 7% increase year-over-year. The company experienced continued execution in its Prevention & Recovery and Reconstructive segments, stable end markets, and positive momentum from new product introductions. Despite a GAAP net loss of $37 million, adjusted EBITDA reached $97 million, reflecting solid operational performance. The company also updated its full-year 2025 financial outlook, raising revenue and adjusted EBITDA guidance.

Enovis delivered a strong first quarter in 2025 with revenues and margins exceeding expectations, driven by continued commercial momentum and growth in both Prevention & Recovery and Reconstructive segments.

Enovis reported a 23% increase in fourth-quarter net sales to $561 million, driven by strong growth in Global Reconstructive. However, the company reported a net loss of $704 million due to a $645 million non-cash goodwill impairment charge. Adjusted EBITDA increased to $113 million, representing 20% of sales.

Enovis reported strong third-quarter results with a 21% increase in sales and significant growth in the Reconstructive segment. The company is focusing on shifting from integration to growth, supported by new product introductions.

Enovis reported a strong second quarter with a 23% increase in sales and adjusted margin expansion. The company reported a net loss of $0.34 per share, but adjusted net income per diluted share was $0.62. Enovis is on track to accelerate growth and profitability into 2025.

Enovis reported a strong start to 2024 with a 27% increase in sales and significant adjusted margin expansion. The acquisition of LimaCorporate S.p.A. was a key highlight, with integration progressing as planned. The company's revenue and operating margins exceeded expectations.

Enovis reported an 11% increase in fourth-quarter net sales, reaching $455 million, with 8% organic growth. Net income from continuing operations was $3 million, or $0.05 per share, and adjusted earnings per diluted share were $0.79. The company's full-year net sales grew 9% to $1.7 billion, with an adjusted EBITDA margin increase.

Enovis reported a 9% increase in third-quarter sales to $418 million, driven by strong growth in the Reconstructive segment and stability in the Prevention and Recovery segment. The company's adjusted EBITDA margin improved by 80 basis points, and adjusted earnings per diluted share were $0.56. Enovis raised its full-year outlook for organic revenue growth and adjusted EBITDA.

Enovis reported strong second-quarter results with 8% sales growth and significant EBITDA margin expansion. The reconstructive segment grew by 18%, and the prevention and recovery segment grew by 4%. The company has raised its full-year outlook for revenue and adjusted EPS.

Enovis reported strong Q1 2023 results with 8% sales growth and 9% organic growth. The Reconstructive segment grew by 19% organically, while the Prevention and Recovery segment grew by 4% organically. The company's adjusted EPS was $0.44, and they have increased their 2023 financial outlook.

Enovis reported a 2% increase in fourth-quarter sales to $409 million, with 5% organic growth. The Reconstructive segment grew 12%. The company reported a net loss from continuing operations of $55 million, or $0.71 per diluted share, and adjusted earnings per share of $0.72.

Enovis reported a 7% increase in net sales to $384 million, with organic growth also at 7%. Adjusted earnings per share increased by 34% to $0.59. The company experienced a net loss of $(1.22) per diluted share. They updated 2022 outlook to include organic growth of approximately 6.5%, total sales growth of approximately 10%, adjusted EBITDA of $235-$240 million, and adjusted earnings per share of $2.20-$2.25.

Enovis reported a net sales increase of 11% to $395 million in Q2 2022, with organic growth of 3%. The company's operating income was $6 million, and adjusted EBITDA increased by 11% to $56 million. Adjusted earnings per share expanded by 44% to $0.59, including a one-time tax benefit.

Colfax Corporation reported Q4 net income from continuing operations of $10 million, or $0.06 per share, compared to $41 million, or $0.29 per share, in the prior year period. Adjusted earnings of $0.59 per share rose 16% from $0.51 in the prior year period. Sales of $1,023 million increased 24%, or 16% on an organic sales-per-day basis versus the prior year period.

Colfax Corporation announced strong third-quarter results with a 20% increase in sales to $966 million and a 32% rise in adjusted EPS to $0.54. The company reported net income from continuing operations of $27 million, or $0.17 per share. Strong progress was reported on the integration of acquisitions, and the company is on track for its Q1 2022 separation, announcing its new name, Enovis.

Colfax Corporation reported a strong second quarter in 2021, with a significant increase in net sales and adjusted EPS. The company's performance led to an increased full-year outlook and strategic acquisition of Mathys Bettlach AG.

Colfax Corporation reported strong first-quarter results with an 8% increase in sales and a 16% rise in adjusted EPS. The company's performance was driven by increased demand and margin expansion in ESAB, as well as improved market conditions and share gains in the MedTech segment. Colfax is raising the low-end of its adjusted 2021 EPS guidance range to $2.05-$2.15.

Colfax Corporation announced strong Q4 2020 results with net sales of $828 million and adjusted EPS of $0.51. The company also completed the acquisition of two medical technology businesses and provided a positive 2021 growth outlook.

Colfax reported net sales of $806 million and net income from continuing operations of $16.0 million, or $0.12 per share. Adjusted EPS was $0.41. The Medical Technology segment achieved 2% reported growth, and the company signed an agreement to acquire extremity product lines with annual revenue of $20 million.

Colfax Corporation reported a net loss of $3.6 million, or $(0.03) per share. Adjusted EPS was $0.09, compared to $0.54 in the second quarter of 2019. Net sales were $620 million, a 32% decrease compared to the previous year. The company generated $37 million in operating cash flow and $18 million in free cash flow.

Colfax Corporation reported a net sales increase of 19.4% to $816 million compared to the previous year's quarter. The company reported $0.06 EPS from continuing operations and achieved $0.38 of adjusted EPS. The company has withdrawn its 2020 financial guidance due to COVID-19.

Colfax Corporation reported Q4 2019 results with net sales of $888 million, a 54.5% increase year-over-year, driven by the acquisition of DJO. The company reported EPS of $0.24 and adjusted EPS of $0.61. The Medical Technology segment saw a 7.5% sales increase, while the Fabrication Technology segment improved adjusted EBITA margins by 320 basis points.